Recently, considerable efforts including antisense[16], ribozymes[17], RNAi-mediated[18,19] survivin knock-down, survivin-directed vaccines[20] or dominant negative mutants[16,21] have been made to counteract survivin in tumor cells in order to inhabit tumor growth potential and enhance tumor cell response to apoptosis-inducing anti-cancer agents. This evidence concerns the gene BIRC5 and cancer.